BFM
KLDO

Boothbay Fund Management’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Boothbay Fund Management’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,108
Closed -$55K – 2419
2021
Q3 		$55K Buy
+10,108
New +$62.7K ﹤0.01% 1837

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Boothbay Fund Management's KLDO Position: Q4 2021 in Review

Boothbay Fund Management sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q4 2021, closing a stake of 10,108 shares — an estimated $55K sold.

Boothbay Fund Management first reported a position in KLDO in Q3 2021 and held it in 1 quarter. The position peaked at $55K in Q3 2021. 66 funds tracked by Wall St. Rank hold KLDO as of Q4 2021.

  • Boothbay Fund Management reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Boothbay Fund Management sold 10,108 Kaleido Biosciences, Inc. Common Stock shares in Q4 2021, an estimated $55K.
  • Boothbay Fund Management first reported a position in Kaleido Biosciences, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Boothbay Fund Management's Kaleido Biosciences, Inc. Common Stock position peaked at $55K in Q3 2021.
  • 66 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q4 2021.

Based on Boothbay Fund Management's 13F filing for Q4 2021, filed 14 Feb 2022.